GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Scilex Holding Co (NAS:SCLX) » Definitions » Beneish M-Score

SCLX (Scilex Holding Co) Beneish M-Score : -6.29 (As of Mar. 05, 2025)


View and export this data going back to 2022. Start your Free Trial

What is Scilex Holding Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -6.29 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Scilex Holding Co's Beneish M-Score or its related term are showing as below:

SCLX' s Beneish M-Score Range Over the Past 10 Years
Min: -8.38   Med: -7.57   Max: -6.29
Current: -6.29

During the past 5 years, the highest Beneish M-Score of Scilex Holding Co was -6.29. The lowest was -8.38. And the median was -7.57.


Scilex Holding Co Beneish M-Score Historical Data

The historical data trend for Scilex Holding Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scilex Holding Co Beneish M-Score Chart

Scilex Holding Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
- - - - -7.37

Scilex Holding Co Quarterly Data
Dec19 Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.57 -7.37 -8.38 -7.97 -6.29

Competitive Comparison of Scilex Holding Co's Beneish M-Score

For the Drug Manufacturers - General subindustry, Scilex Holding Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scilex Holding Co's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Scilex Holding Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Scilex Holding Co's Beneish M-Score falls into.



Scilex Holding Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Scilex Holding Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.5755+0.528 * 0.9326+0.404 * 0.9007+0.892 * 1.2202+0.115 * 0.9094
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.7338+4.679 * -0.959972-0.327 * 1.0029
=-6.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Total Receivables was $31.58 Mil.
Revenue was 14.436 + 16.37 + 10.884 + 13.462 = $55.15 Mil.
Gross Profit was 10.668 + 11.98 + 7.044 + 8.941 = $38.63 Mil.
Total Current Assets was $39.86 Mil.
Total Assets was $100.43 Mil.
Property, Plant and Equipment(Net PPE) was $3.11 Mil.
Depreciation, Depletion and Amortization(DDA) was $4.08 Mil.
Selling, General, & Admin. Expense(SGA) was $107.13 Mil.
Total Current Liabilities was $281.54 Mil.
Long-Term Debt & Capital Lease Obligation was $16.05 Mil.
Net Income was -4.388 + -37.582 + -24.377 + -21.4 = $-87.75 Mil.
Non Operating Income was 18.605 + -21.388 + 2.523 + -2.502 = $-2.76 Mil.
Cash Flow from Operations was 5.113 + 2.311 + 9.391 + -5.39 = $11.43 Mil.
Total Receivables was $16.43 Mil.
Revenue was 10.117 + 12.582 + 10.582 + 11.919 = $45.20 Mil.
Gross Profit was 6.725 + 8.405 + 6.991 + 7.406 = $29.53 Mil.
Total Current Assets was $25.48 Mil.
Total Assets was $80.53 Mil.
Property, Plant and Equipment(Net PPE) was $3.89 Mil.
Depreciation, Depletion and Amortization(DDA) was $4.15 Mil.
Selling, General, & Admin. Expense(SGA) was $119.65 Mil.
Total Current Liabilities was $228.58 Mil.
Long-Term Debt & Capital Lease Obligation was $9.33 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(31.58 / 55.152) / (16.428 / 45.2)
=0.572599 / 0.363451
=1.5755

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(29.527 / 45.2) / (38.633 / 55.152)
=0.653252 / 0.700482
=0.9326

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (39.855 + 3.107) / 100.43) / (1 - (25.481 + 3.889) / 80.528)
=0.572219 / 0.635282
=0.9007

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=55.152 / 45.2
=1.2202

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(4.147 / (4.147 + 3.889)) / (4.076 / (4.076 + 3.107))
=0.516053 / 0.567451
=0.9094

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(107.13 / 55.152) / (119.645 / 45.2)
=1.94245 / 2.647013
=0.7338

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((16.046 + 281.537) / 100.43) / ((9.334 + 228.58) / 80.528)
=2.963089 / 2.954426
=1.0029

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-87.747 - -2.762 - 11.425) / 100.43
=-0.959972

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Scilex Holding Co has a M-score of -6.29 suggests that the company is unlikely to be a manipulator.


Scilex Holding Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Scilex Holding Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Scilex Holding Co Business Description

Traded in Other Exchanges
N/A
Address
960 San Antonio Road, Palo Alto, CA, USA, 94303
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
Executives
Jaisim Shah director, officer: See Remarks C/O PROTINE DESIGN LAB, 37481 MARSTEN DR, NEWARK CA 94560
Henry Ji director, officer: Executive Chairperson 5370 RUETTE DE MER, SAN DIEGO CA 92130
Jay Chun director C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Dorman Followwill director C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121
Yue Alexander Wu director C/O SORRENTO THERAPEUTICS, INC., 9380 JUDICIAL DRIVE, SAN DIEGO CA 92121
David Lemus director C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121
Stephen Hoi Ma officer: Chief Financial Officer C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Sclx Stock Acquisition Jv Llc 10 percent owner 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105
Tien-li Lee director C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Sorrento Therapeutics, Inc. 10 percent owner 4955 DIRECTORS PLACE, SAN DIEGO CA 92121
Elizabeth Czerepak officer: See Remarks 201 ROUTE 17 NORTH, RUTHERFORD NJ 07070
Laura Hamill director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Steve Myint director C/O VICKERS VANTAGE CORP. I, 1 HARBOURFRONT AVENUE, #16-06, SINGAPORE U0 098632
Chris Ho director, 10 percent owner, officer: Chief Financial Officer C/O VICKERS VANTAGE CORP. I, 1 HARBOURFRONT AVENUE, #16-06, SINGAPORE U0 098632

Scilex Holding Co Headlines

From GuruFocus